Evidence map›Paper›PMID 27008338›Full record

ArticleACS chemical biology2016

Thymidylate Limitation Potentiates Cephalosporin Activity toward Enterococci via an Exopolysaccharide-Based Mechanism.

Jessica S Hoff, Christopher J Kristich

Abstract read
In one paragraph

Article in ACS chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. mBio · 2026
    Article
  2. bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Frontiers in microbiology · 2021
    Article
  5. Article
  6. Article
  7. Restructuring ofNPJ biofilms and microbiomes · 2017
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jessica S HoffDepartment of Microbiology and Molecular Genetics, Medical College of Wisconsin , Milwaukee, Wisconsin, United States.
Christopher J KristichDepartment of Microbiology and Molecular Genetics, Medical College of Wisconsin , Milwaukee, Wisconsin, United States.
Medical College of Wisconsin · US

Funding

Intrinsic Resistance to antimicrobials in Enterococcus faecalisR01AI081692 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI KRISTICH, CHRISTOPHER J · 2010 to 2014
$1.9M
Impact of nucleotide metabolism on enterococcal antibiotic resistanceR21AI109198 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI KRISTICH, CHRISTOPHER J · 2014 to 2015
$421k
NIAID NIH HHS R01 AI081692NIAID NIH HHS R21 AI109198
6 · The paper itself

Abstract

Multidrug resistant enterococci are major causes of nosocomial infections. Prior therapy with cephalosporins increases the risk of developing an enterococcal infection due to the intrinsic resistance of enterococci to these antibiotics. While progress has been made toward understanding the genetic and biochemical mechanisms of cephalosporin resistance, available data indicate that as-yet-unidentified resistance factors must exist. Here, we describe results of a screen to identify small molecules capable of sensitizing enterococci to broad-spectrum cephalosporins. We found that both Enterococcus faecalis and Enterococcus faecium were sensitized to broad and expanded-spectrum cephalosporins when thymidylate production was impaired, whether by direct inhibition of thymidylate synthase, or by limiting production of cofactors required for its activity. Cephalosporin potentiation is the result of altered exopolysaccharide production due to reduced dTDP-glucose synthesis. Hence, exopolysaccharide production is a previously undescribed contributor to the intrinsic cephalosporin resistance of enterococci and serves as a new target for antienterococcal therapeutics.

Indexed as

Anti-Bacterial AgentsCell WallCephalosporinsChloramphenicolDrug Resistance, Multiple, BacterialDrug SynergismEnterococcus faecalisEnterococcus faeciumFluorouracilFolic Acid AntagonistsGlucosePolysaccharidesQuinazolinesTetrahydrofolate DehydrogenaseThymidine MonophosphateThymidylate Synthase5-(4-fluorophenoxy)quinazoline-2,4-diamine5-(4-methylphenyl)sulfanylquinazoline-2,4-diamineAnti-Bacterial AgentsCephalosporinsChloramphenicoldeoxythymidine diphosphate-glucoseFluorouracilFolic Acid AntagonistsGlucosePolysaccharidesQuinazolinesTetrahydrofolate DehydrogenaseThymidine MonophosphateThymidylate SynthaseThymine NucleotidesTrimethoprim

Identifiers

PMID27008338
PMCPMC5238413
OpenAlexW2307532366

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.